Indivior PLC INDV

LON: INDV | ISIN: GB00BN4HT335 31/05/2024

1.445,00 GBX (+0,84%)

(+0,84%) 31/05/2024

Grafiek Indivior PLC

Grafiek Indivior PLC

1 dag1d 0,84%
1 week1w 1,19%
1 maand1m 0,70%
3 maanden3m -16,71%
6 maanden6m 9,55%
1 jaar1j -9,12%
5 jaar5j 547,26%

Indivior PLC in het nieuws

Toon enkel gratis nieuws

23 mei 2024 · Indivior to Host Analyst Teach-in Event in New York City; Reconfirms Full Year 2024 Guidance · Persbericht

25 april 2024 · Indivior Announces Q1 2024 Financial Results · Persbericht

11 maart 2024 · Indivior Announces Publication Demonstrating that OPVEE® (nalmefene) Nasal Spray Rapidly Reverses Effects of Opioid-Induced Respiratory Depression in Head-to-Head Study Against Intranasal Naloxone · Persbericht

29 februari 2024 · Court Provides Final Approval of Settlement with Direct Purchaser Class in the Multidistrict Antitrust Litigation; Final Court Approval Concludes the Antitrust Multidistrict Litigation · Persbericht

22 februari 2024 · Indivior Announces Q4 / FY 2023 Financial Results · Persbericht

9 november 2023 · Indivior Announces Q3 2023 Financial Results · Persbericht

11 oktober 2023 · Indivior Enters an Exclusive Licensing Agreement with Alar Pharmaceuticals · Persbericht

26 september 2023 · Indivior Publishes Real World Data Showing SUBLOCADE® May Reduce Non-Fatal Overdoses Among Individuals with Opioid Use Disorder in Canada · Persbericht

21 augustus 2023 · Indivior Reaches Agreement with End Payor Class to Resolve Their Antitrust Multi-District Litigation Claims · Persbericht

27 juli 2023 · Indivior Announces Q2/H1 2023 Financial Results · Persbericht

Profiel Indivior PLC

Farmaceutische producten: Andere

Gezondheidstechnologie

Medicinale en botanische productie

CEO: Shaun Thaxter

Aandelen Indivior PLC

Beurswaarde: 1,95 miljard GBP

Effecten: 134,76 miljoen

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe